Adding Cetuximab in Esophageal Cancer Fails to Improve Survival

Use of the EGFR inhibitor cetuximab with chemoradiation did not improve survival in patients with esophageal carcinoma compared with chemoradiation alone, according to the results of the phase III RTOG 0436 trial.

Source: CancerNetwork - July 13, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Esophageal Cancer Gastrointestinal Cancer News Source Type: news